Cybin announces additional strategic clinical site partnerships to support paradigm, a multinational phase 3 program evaluating cyb003

Toronto--(business wire)--cybin inc. (nyse american:cybn) (cboe ca:cybn) (“cybin” or the “company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced additional strategic partnership agreements (“spas”), bringing the total to 18 clinical sites engaged to advance cybin's multinational phase 3 program evaluating cyb003 for the adjunctive treatment of mdd.
CYBN Ratings Summary
CYBN Quant Ranking